Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.
Progenics Pharmaceuticals, Inc. (“Progenics”) has prepared presentation materials (the “Presentation Materials”) that management intends to use from time to time on and after January 4, 2019, in presentations about Progenics’ operations and performance. Progenics may use the Presentation Materials in presentations to current and potential investors, lenders, creditors, insurers, vendors, customers, employees, and others with an interest in Progenics and its business. The Presentation Materials are furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained in the Presentation Materials is summary information that should be considered within the context of Progenics’ filings with the U.S. Securities and Exchange Commission and other public announcements that Progenics may make by press release or otherwise from time to time. The Presentation Materials speak as of the date of this Current Report on Form 8-K. While Progenics may elect to update the Presentation Materials in the future or reflect events and circumstances occurring or existing after the date of this Current Report on Form 8-K, Progenics specifically disclaims any obligation to do so.
The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01Financial Statements and Exhibits
(d)Exhibits.
|
Exhibit No. |
Description |
|
99.1 |
Investor presentation materials. |
PROGENICS PHARMACEUTICALS INC Exhibit
…
To view the full exhibit click here
About Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)
Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases. The Company’s EXINI Bone BSI is an analytical tool that employs an artificial intelligence-based approach to apply techniques of statistical analysis and pattern recognition to quantify the information produced by bone scintigraphy (bone scan) images used to view cancer present in the skeleton. The EXINI Bone BSI tool reads bone scans and produces an automated Bone Scan Index quantification. The Company’s clinical-stage products include AZEDRA, 1404 (trofolastat), PyL ([18F] DCFPyL), 1095 and PSMA ADC. The Company’s partnered products include Relistor-Subcutaneous injection, Relistor-Oral Tablets and PRO 140.